MA44061A - Molécules d'anticorps multispécifiques ayant une spécificité pour tnf-alpha, il-17a et il-17f - Google Patents

Molécules d'anticorps multispécifiques ayant une spécificité pour tnf-alpha, il-17a et il-17f

Info

Publication number: MA44061A
Authority: MA; Morocco
Prior art keywords: tnf; specificity; alpha; antibody molecules; multispecific antibody
Prior art date: 2015-12-18

Application number

MA044061A

Other languages

English (en)

Inventor

Ralph Adams

Pallavi Bhatta

Emma Dave

Sam Philip Heywood

David Paul Humphreys

Daniel John Lightwood

Diane Marshall

Stevan Graham Shaw

Original Assignee

Ucb Biopharma Sprl

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-12-18

Filing date

2016-12-14

Publication date

2018-10-24

2016-12-14 Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl

2018-10-24 Publication of MA44061A publication Critical patent/MA44061A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Physical Education & Sports Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

MA044061A 2015-12-18 2016-12-14 Molécules d'anticorps multispécifiques ayant une spécificité pour tnf-alpha, il-17a et il-17f MA44061A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB1522391.0A GB201522391D0 (en)	2015-12-18	2015-12-18	Antibody molecules

Publications (1)

Publication Number	Publication Date
MA44061A true MA44061A (fr)	2018-10-24

Family

ID=55311227

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA42743A MA42743A1 (fr)	2015-12-18	2016-12-14	Molécules d'anticorps multispécifiques ayant une spécificité pour tnf-alpha, il-17a et il-17f
MA044061A MA44061A (fr)	2015-12-18	2016-12-14	Molécules d'anticorps multispécifiques ayant une spécificité pour tnf-alpha, il-17a et il-17f

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
MA42743A MA42743A1 (fr)	2015-12-18	2016-12-14	Molécules d'anticorps multispécifiques ayant une spécificité pour tnf-alpha, il-17a et il-17f

Country Status (25)

Country	Link
US (1)	US20200277366A1 (fr)
EP (1)	EP3390445A1 (fr)
JP (1)	JP2019502380A (fr)
KR (1)	KR20180089514A (fr)
CN (1)	CN108473568A (fr)
AR (1)	AR107735A1 (fr)
AU (1)	AU2016369307A1 (fr)
BR (1)	BR112018011860A2 (fr)
CA (1)	CA3007493A1 (fr)
CL (1)	CL2018001660A1 (fr)
CO (1)	CO2018006667A2 (fr)
EA (1)	EA201891446A1 (fr)
EC (1)	ECSP18054047A (fr)
GB (1)	GB201522391D0 (fr)
IL (1)	IL259645A (fr)
MA (2)	MA42743A1 (fr)
MX (1)	MX2018007289A (fr)
PH (1)	PH12018501141A1 (fr)
RU (1)	RU2018126318A (fr)
SG (1)	SG11201804803WA (fr)
TN (1)	TN2018000200A1 (fr)
TW (1)	TW201726731A (fr)
UY (1)	UY37035A (fr)
WO (1)	WO2017102830A1 (fr)
ZA (1)	ZA201803681B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY207225A (en)	2015-10-27	2025-02-06	UCB Biopharma SRL	Methods of treatment using anti-il-17a/f antibodies
GB201522394D0 (en)	2015-12-18	2016-02-03	Ucb Biopharma Sprl	Antibodies
RU2680011C2 (ru) *	2016-04-29	2019-02-14	Закрытое Акционерное Общество "Биокад"	Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
US20200087390A1 (en)	2016-12-21	2020-03-19	Amgen Inc.	Anti-tnf alpha antibody formulations
GB201719447D0 (en) *	2017-11-23	2018-01-10	Ucb Biopharma Sprl	Pharmaceutical composition
CN110551215A (zh) *	2018-05-30	2019-12-10	中山康方生物医药有限公司	抗白细胞介素-17a抗体、其药物组合物及其用途
EP4591879A3 (fr) *	2019-01-31	2025-10-22	Numab Therapeutics AG	Anticorps multispécifiques ayant une spécificité pour tnfa et il-17a, anticorps ciblant il-17a, et leurs procédés d'utilisation
CN113416258B (zh) *	2019-10-24	2023-08-29	北京免疫方舟医药科技有限公司	一种多特异性抗体及其制备方法和用途
KR20210095781A (ko) *	2020-01-24	2021-08-03	주식회사 에이프릴바이오	항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
JP2024510098A (ja) *	2021-02-19	2024-03-06	イノベントバイオロジクス（スーチョウ）カンパニー，リミティド	抗ＧＰＲＣ５ＤｘＢＣＭＡｘＣＤ３三重特異性抗体およびその使用
CN117642423A (zh) *	2021-09-13	2024-03-01	深圳华普药物研发有限公司	一种il17抗体及其制备方法和应用
CN114380917B (zh) *	2022-03-25	2022-06-14	南京融捷康生物科技有限公司	针对IL-17A和TNFα的双特异性单域抗体及其用途
WO2025248017A1 (fr) *	2024-05-31	2025-12-04	UCB Biopharma SRL	Procédé de purification de protéines de recombinaison

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7790163B2 (en) *	2006-03-10	2010-09-07	Zymogenetics, Inc.	Antibodies that bind both IL-17A and IL-17F and methods of using the same
CA2721713C (fr) *	2008-05-05	2019-07-09	Novimmune Sa	Anticorps a reaction croisee anti-il-17a/il-17f et leurs procedes d'utilisation
UA117218C2 (uk) *	2011-05-05	2018-07-10	Мерк Патент Гмбх	Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
BR112014009810A2 (pt) *	2011-10-24	2017-04-25	Abbvie Inc	imunoligantes biespecíficos dirigidos contra tnf e il-17
TW201444867A (zh) *	2013-03-08	2014-12-01	Lilly Co Eli	抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體
EP3027649B1 (fr) *	2013-08-01	2020-04-01	F.Hoffmann-La Roche Ag	Anticorps bispécifiques tnfa-il-17

2015
- 2015-12-18 GB GBGB1522391.0A patent/GB201522391D0/en not_active Ceased
2016
- 2016-12-14 CA CA3007493A patent/CA3007493A1/fr not_active Abandoned
- 2016-12-14 SG SG11201804803WA patent/SG11201804803WA/en unknown
- 2016-12-14 TN TNP/2018/000200A patent/TN2018000200A1/en unknown
- 2016-12-14 MA MA42743A patent/MA42743A1/fr unknown
- 2016-12-14 EP EP16822624.9A patent/EP3390445A1/fr not_active Withdrawn
- 2016-12-14 JP JP2018531446A patent/JP2019502380A/ja not_active Abandoned
- 2016-12-14 AU AU2016369307A patent/AU2016369307A1/en not_active Abandoned
- 2016-12-14 BR BR112018011860-5A patent/BR112018011860A2/pt not_active Application Discontinuation
- 2016-12-14 KR KR1020187020510A patent/KR20180089514A/ko not_active Withdrawn
- 2016-12-14 MA MA044061A patent/MA44061A/fr unknown
- 2016-12-14 MX MX2018007289A patent/MX2018007289A/es unknown
- 2016-12-14 US US16/063,108 patent/US20200277366A1/en not_active Abandoned
- 2016-12-14 WO PCT/EP2016/080979 patent/WO2017102830A1/fr not_active Ceased
- 2016-12-14 CN CN201680079820.1A patent/CN108473568A/zh active Pending
- 2016-12-14 RU RU2018126318A patent/RU2018126318A/ru not_active Application Discontinuation
- 2016-12-14 EA EA201891446A patent/EA201891446A1/ru unknown
- 2016-12-16 TW TW105141750A patent/TW201726731A/zh unknown
- 2016-12-16 UY UY0001037035A patent/UY37035A/es not_active Application Discontinuation
- 2016-12-16 AR ARP160103878A patent/AR107735A1/es unknown
2018
- 2018-05-28 IL IL259645A patent/IL259645A/en unknown
- 2018-05-31 PH PH12018501141A patent/PH12018501141A1/en unknown
- 2018-06-01 ZA ZA2018/03681A patent/ZA201803681B/en unknown
- 2018-06-18 CL CL2018001660A patent/CL2018001660A1/es unknown
- 2018-06-27 CO CONC2018/0006667A patent/CO2018006667A2/es unknown
- 2018-07-18 EC ECSENADI201854047A patent/ECSP18054047A/es unknown

Also Published As

Publication number	Publication date
CA3007493A1 (fr)	2017-06-22
CL2018001660A1 (es)	2018-10-19
WO2017102830A1 (fr)	2017-06-22
US20200277366A1 (en)	2020-09-03
JP2019502380A (ja)	2019-01-31
PH12018501141A1 (en)	2019-01-28
EA201891446A1 (ru)	2018-11-30
MX2018007289A (es)	2018-09-28
ZA201803681B (en)	2019-09-25
BR112018011860A2 (pt)	2018-12-04
ECSP18054047A (es)	2018-07-31
RU2018126318A3 (fr)	2020-05-20
TW201726731A (zh)	2017-08-01
EP3390445A1 (fr)	2018-10-24
GB201522391D0 (en)	2016-02-03
TN2018000200A1 (en)	2019-10-04
MA42743A1 (fr)	2019-07-31
RU2018126318A (ru)	2020-01-20
IL259645A (en)	2018-07-31
CN108473568A (zh)	2018-08-31
KR20180089514A (ko)	2018-08-08
AR107735A1 (es)	2018-05-30
SG11201804803WA (en)	2018-07-30
CO2018006667A2 (es)	2018-07-10
UY37035A (es)	2017-07-31
AU2016369307A1 (en)	2018-07-12

Publication	Publication Date	Title
IL264142A (en)	2019-02-28	Multispecific antibodies against cd40 and cd137
ZA201803681B (en)	2019-09-25	Multi-specific antibody molecules having specificity for tnf-alpha, il-17a and il-17f
IL263690A (en)	2019-01-31	Purification of multispecific antibodies
EA202092435A2 (ru)	2021-02-26	Моноклональные антитела против bcma
IL256416B (en)	2021-12-01	Multispecific antigen-binding molecules and uses thereof
DK3428194T3 (da)	2021-11-15	Forbedret polypeptidmolekyle med dobbelt specificitet
MA44381A (fr)	2019-01-23	Format d'anticorps hétérodimères multispécifiques
AR101845A1 (es)	2017-01-18	Anticuerpos anti-her2 e inmunoconjugados
MA50352A (fr)	2020-08-19	Anticorps multispécifiques
IL264161A (en)	2019-02-28	Tgfb antibodies, methods, and uses
DK3356401T3 (da)	2020-09-07	Bindingsmolekyler med modificeret j-kæde
EA201791029A1 (ru)	2017-12-29	Антитела против интерлейкина-33 и их применение
EA201300819A1 (ru)	2014-01-30	Молекулы антител, которые связываются с il-17a и il-17f
CL2016002455A1 (es)	2017-08-11	Anticuerpos multiespecíficos.
EP3277711C0 (fr)	2023-06-07	Domaines de répétition d'ankyrine artificiels ayant une spécificité de liaison pour l'albumine sérique
DK3355913T3 (da)	2024-12-02	Bindingsmolekyler med modificeret j-kæde
HUE051496T2 (hu)	2021-03-01	TL1A-hoz specifikusan kötõdõ ellenanyagok
EA201790505A1 (ru)	2017-07-31	Соединение, нацеленое на ил-23а и фно-альфа, и его применение
MX2016016883A (es)	2018-03-02	Anticuerpo anti-axl.
MX375524B (es)	2025-03-06	Anticuerpos anti-axl.
EA201890747A1 (ru)	2018-10-31	Способы лечения воспалительных заболеваний
MA45656A (fr)	2021-03-24	Nouveaux pyrimidine carboxamides utilisées comme inhibiteurs de l'enzyme vanin-1
EP3830268A4 (fr)	2023-12-13	Molécules d'arn comprenant des paires de bases non canoniques
IL269559A (en)	2019-11-28	Stable multispecific antibodies
EP3673066A4 (fr)	2021-05-26	Molécules d'arn